ArticleExperimental and therapeutic medicine2026
Identification of early diagnostic biomarkers in venous thromboembolism: A bioinformatic analysis based on crosstalk between pyroptosis and venous thromboembolism.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolism (VTE) is a common vascular disease and a major cause of mortality. Development of early diagnostic biomarkers that accurately predict the occurrence of VTE is key for its initial management. The present study was designed to identify potential early diagnostic biomarkers based on the crosstalk between pyroptosis and VTE. The GSE19151 and GSE48000 datasets were utilized as the training and validation cohorts, respectively. Pyroptosis-related genes (PRGs) were sourced from the existing literature. Multiple bioinformatic analyses were conducted to pinpoint key PRGs in VTE. The possible functions of these genes were elucidated through gene set enrichment analysis (GSEA). Molecular regulatory networks were synthesized to probe into the underlying molecular mechanism of VTE. Moreover, a total of 5 pairs of frozen blood samples were analyzed quantifiably by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) to evaluate the expression levels of these biomarkers. a total of Five critical biomarkers (RPL31, RPL34, RPL9, RPS27L and HINT1) were eventually screened, with significantly elevated expression levels observed in VTE samples in both the training and validation cohorts compared with control. The RT-qPCR results further confirmed that expression trends of these genes were consistent with those in the GSE19151 and GSE48000 datasets. GSEA indicated a correlation between the five biomarkers and ribosomal proteins as well as oxidative phosphorylation signaling pathways, suggesting their potential role in triggering VTE by regulating pyroptosis-inflammation-coagulation axis. A total of five critical pyroptosis-related biomarkers have been initially characterized, showing potential for early diagnosis of VTE. While these findings are promising, further investigation into the precise mechanisms and clinical thresholds is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.